China
Africa
Explore chapters and articles related to this topic
Imaging Matrix Metalloproteinase Expression: Applications for Cardiovascular Imaging
Published in Robert J. Gropler, David K. Glover, Albert J. Sinusas, Heinrich Taegtmeyer, Cardiovascular Molecular Imaging, 2007
Copper-64 is a useful diagnostic and therapeutic radionuclide in nuclear medicine due to its half-life (t1/2 = 12.7 h), decay characteristics [β+ (17.4%); β- (39%)] and the ability for large-scale production with high specific activity on a biomedical cyclotron (22,23). 64Cu-DOTA-CTT (where DOTA is 1,4,7,10-tetraaza-cyclododecane-1,4,7,10-tetraacetic acid) was evaluated in a tumor- bearing animal model with limited success (14).
Si-ion implantation effects on the surface hardness and microstructure of brass alloy
Published in Radiation Effects and Defects in Solids, 2022
Muhammad Shahnawaz, Nawaz Muhammad
A total number of five specimens were prepared from brass alloy with composition in %age; copper 64; and zinc balance. Young’s modulus and Poisson’s ratio were 110 GPa and 0.34, respectively. One specimen was kept as reference, whereas the other four were ion implanted with different doses. Samples were square shaped of 1 × 1 cm2, whereas the thickness was 0.1 cm. Samples were grounded finish with SiC emery papers of grids 320, 1000, 2000, 3000 and 4000. After that, the samples were treated with metal polish and washed/rinsed with acetone. The prepared specimens were annealed for 60 min at 300°C. For ion implantation, a Pelletron accelerator of model no. 6SDH-2 was used to generate 500 keV energetic Si-ions. Each sample was implanted on the respective ion dose. The four test specimens were bombarded with different Si-ions doses; (1.68 × 1014, 5.02 × 1014, 6.90 × 1014 and 8.69 × 1014 ions/cm2). The average ion beam was kept as 52 nA and it was done at room temperature under controlled environment of vacuum maintained at 2 × 10−8 Torr.
Determination of experimental Cherenkov spectrum (200–1050 nm) of 18F and its implications on optical dosimetry: murine model
Published in Radiation Effects and Defects in Solids, 2022
Eugenio Torres-García, Hansel Torres-Velazquez, Luis E. Díaz-Sánchez, Liliana Aranda-Lara, Keila Isaac-Olivé
Currently, optical imaging (OI) technique represents a challenge that is being addressed worldwide. This technique uses light to obtain detailed images of organs and smaller structures such as cells and even molecules (1,2). In addition, light has been used as a treatment for disease through photodynamic therapy (3). The Cherenkov effect is the production of light by electrons or beta particles when they pass through a dielectric medium (such as tissue) at a speed greater than that of light in the same medium (4). Cherenkov radiation has been useful to perform OI for Positron Emission Tomography (PET) radionuclides as Fluor-18 (18F), Carbon-11 (11C), Copper-64 (64Cu), Gallium-68 (68Ga), Zirconium-89 (89Zr), etc. (5–7). Also, Cherenkov luminescence imaging modality takes advantage of optical Cherenkov photons, since this light might be used for photoactivation, photodynamic therapy, photothermal therapy, excited fluorophores, etc. (8–10).
Theranostic approaches in nuclear medicine: current status and future prospects
Published in Expert Review of Medical Devices, 2020
Luca Filippi, Agostino Chiaravalloti, Orazio Schillaci, Roberto Cianni, Oreste Bagni
Radiopharmacy is a field that is expected to rapidly evolve in the next few years. In this respect, the radionuclide copper-64 (64Cu) is gaining more and more attention in the scientific community. Copper is an essential element in many metabolic processes involving cell differentiation, metabolism, and growth. Furthermore, human copper transporter 1 (CTR1), a transmembrane protein responsible for copper intracellular incorporation, was found to be overexpressed in many malignancies. 64Cu is a cyclotron-produced radionuclide with an intermediate half-life (12.7 h) that decays by both positronic and beta-particles emission, making it suitable for theranostic applications. The radiopharmaceutical 64CuCl2, a substrate for CTR1, is under investigation with promising results as a potential theranostic agent in several pre-clinical and clinical trials regarding tumors such as melanoma or prostate cancer [90,91].